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ABSTRACT 
 
Background   
Chemotherapeutic agents have been the backbone treatment for pediatric cancers. 
Unfortunately, a number of the chemotherapy medications have potential side effects, 
including chemotherapy-induced peripheral neuropathy (CIPN). To measure the extent of 
CIPN, the Pediatric Modified Total Neuropathy Score (Peds-mTNS) has been shown to 
be a reliable and valid measure of CIPN in school-aged children and is associated with 
relevant functional limitations. However, future research is needed to describe the 
recovery of CIPN in children and adolescent cancer patients after treatment has ended.  
 
Purpose 
To analyze the trajectory of recovery for CIPN in school-aged children diagnosed with 
non-CNS cancers and to evaluate if diagnosis and treatment impact CIPN type and 
recovery.  
 
Methods  
Forty-seven subjects ranging in age from 5-18 years undergoing chemotherapy with 
vincristine or a combination of vincristine and intrathecal methotrexate participated in the 
study.  Peds-mTNS scores as well as standardized balance and hand function measures 
were taken on treatment (at the anticipated peak of CIPN) and then 3 and 6 months post 
treatment. Descriptive statistics and one-way repeated measures ANOVA were run to 
compare subjects over time (on treatment, 3 months, and 6 months post). A 2-way 
 
 III 
repeated measures ANOVA was run to compare mean Peds-mTNS scores for each 
diagnostic group over time.  
 
Results  
18 subjects with Acute Lymphoblastic Leukemia (ALL), 8 with Wilma’ tumor, 14 with 
non/Hodgkin’s lymphoma and 7 with other non-CNS cancers were evaluated. Across all 
subjects (n=47), Peds-mTNS scores decreased significantly over time (on treatment 9.5± 
4.4, 3 months 5.8 ± 4.7, 6 months 4.3 ± 4.0, p< 0.001), indicating an improvement in 
CIPN. Overall effect size, with Partial Eta Squared, was found to be large 
(0.609).  Greatest individual measure effect size was shown in deep tendon reflex 
(.659).  Of the diagnostic groups, patients with Hodgkin’s lymphoma were found to have 
significantly less improvement on the Peds-mTNS than subjects with leukemia (6.4 ± 0.7 
vs 2.2 ± 0.6 at 6 months, p<0.05), even though their treatment time was shorter in 
duration and they received less vincristine.    
 
Conclusion  
Overall, the trajectory of recovery for pediatric cancer patients was found to be positive, 
resulting in significant improvements in CIPN symptoms over time post-treatment, 
although patients with Hodgkin’s lymphoma were more likely to have residual 
neuropathy. 
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Chapter I: Introduction and Literature Review 
In 2014 it was estimated that 15,780 new cases of pediatric (ages 0-19 years) 
cancer occurred in the U.S.
1 
From this same set of statistics, the National Cancer Institute, 
it was determined that nearly 2,000 of them would die from their malignancy.
1
 Given the 
high occurrence in the pediatric population, the focus of this study is on the most 
common types of cancer. These are, in order of rate of prevalence: leukemia (including 
both acute lymphoblastic and acute myelogenous subtypes), Hodgkin’s lymphoma, non-
Hodgkin’s lymphoma, and Wilma’ tumor. Patients affected by cancers of the brain, 
although also prevalent, were not included in the study. This is partially because the 
complex circuitry of the brain warrants its own study, but also because other neurological 
deficits due to the tumor location in this population can confound the evaluation of 
symptoms. 
Leukemia is a cancer of the bone marrow and blood, and can be split into two 
main subgroups: Acute Lymphoblastic Leukemia (ALL) and Acute Myelogenous 
Leukemia (AML). ALL is the most common type, affecting 3 out of 4 patients with 
leukemia. ALL is a fast growing cancer of the lymphoid cells in bone marrow. The 
population that is most frequently diagnosed with ALL is Caucasian females. AML 
accounts for the remainder of patients diagnosed with leukemia. This type of cancer is 
fast growing and appears in the myeloid cells that create leukocytes, erythrocytes, and 
platelets.
2
 Treatment for leukemia includes chemotherapy, radiation, and blood 
transplants or bone marrow transplants.
3
 The cause of leukemia is unknown at this time.
3
 
The 5-year survival rate for ALL is 80%, while the survival rate for AML is 60-70%, as 
 
 
2 
 
stated by the American Cancer Association.
2
 Survival rates for both ALL and AML have 
increased with the advancement in the medical treatment for pediatric cancer.
2
 
Wilma’ Tumor, first discovered by Dr. Thomas Wilma, presents on the kidneys 
most often in a unilateral growth but can affect both kidneys. It is common in young 
children 3-4 years old with a higher prevalence in African-American females. A primary 
sign of the tumor may be swelling or hardening of a child’s abdomen.
2 
The most common 
treatment for Wilma’ tumors is surgical removal combined with chemotherapy (before or 
after the surgery), and usually radiation therapy is only used in more advanced cases.
2
 
According to the American Cancer Association the survival rate for Wilma’ Tumor after 
surgery is 90%.
2
 
Non-Hodgkin’s Lymphoma (NHL) is more common in older teens, with a higher 
diagnosis rate in Caucasians and males.
2
 This type of cancer affects the lymph system, 
made up of the spleen, thalamus, tonsils/adenoids, and lymph nodes. A primary risk 
factor for this cancer is a weak immune system either from birth or developed over a 
period of time.
2
 The signs and symptoms of NHL vary depending on the location of the 
cancer. Some patients may show swelling in the lymph node areas; this can cause fluid to 
build up and may cause pain. Key signs include fever, chills (mostly at night), and 
unexplained weight loss.  Chemotherapy is the main form of treatment with this cancer; 
the use of surgery and radiation are used on a smaller scale.
2
  
Hodgkin’s Lymphoma, also known as Hodgkin’s disease, is different from NHL 
in its growth and treatment. The population more at risk for developing Hodgkin's are 
males in their 20’s from a higher socioeconomic status.
2
 Hodgkin’s lymphoma typically 
 
 
3 
 
occurs in the upper portion of the body in areas of the neck, chest, and underarms. The 
cancerous cells develop from mutated B-lymphocytes, named Reed-Sternberg cells after 
the doctors that discovered them.
2
 Hodgkin’s types can be split into two main groups: 
Classic Hodgkin's disease and Nodular Hodgkin’s disease.  While the latter only makes 
up 5% of the cases, Classic Hodgkin's disease makes up 95% of cases and has four 
subgroups. The most prevalent of these subtypes is Nodular Sclerosis Hodgkin's disease, 
and makes up 60-80% of classic Hodgkin’s diagnoses.
2
 The varying types of Hodgkin’s 
lymphoma can be differentiated by viewing the cancer cells under a microscope.
2
 The 
two most common forms of treatment for this type of cancer are chemotherapy or 
radiation. 
With the advances in the medical treatment of cancers, more people are reaching 
the 5 year survival marker than in years past. As stated by the National Cancer Institute, 
children diagnosed with cancer had a 58.1% of reaching the 5 year survival marker in 
1975-77. The rate increased to over 80% in 2010,
1 
a statistic echoed by the American 
Cancer Society. With more children surviving cancer, health care providers are becoming 
more aware of the long-term functional deficits showing up in survivors.   
 
Treatment/Medications 
As previously mentioned, the survival rates of pediatric cancer patients have 
continued to climb steadily over the years. These increases are largely due to the use of 
multimodal therapy, using active chemotherapeutic agents.
4
 Chief among these agents are 
vincristine, and intrathecal methotrexate, which will be the key medications focused upon 
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in this review. Other agents that are also used less frequently are taxanes, bortezomib, 
thalidomide, and a variety of platinum compounds. 
Vincristine is a medication that directly affects cells by depolymerizing 
microtubules, which are responsible for a cell’s overall structure. Vincristine is primarily 
used for the treatment of: leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, Wilma’ 
tumor, neuroblastoma, and rhabdomyosarcoma.
4  
It can be administered intravenously via 
PICC line, catheter, or cannula.
6  
It is considered a “backbone” of therapy in both the 
initial (induction) and secondary (consolidation) phases of pediatric malignancies, even 
though neurotoxic side effects are common.”
7
 In adults it has been shown to cause 
abnormal function of A-beta, A-delta, and C-fiber sensory afferents.
8
  
Methotrexate attacks cancer cells by protein-mediated endocytosis. It can be used 
intrathecally to treat cancer cells hidden in the central nervous system (CNS). Evidence 
suggests that several mechanisms of methotrexate play a role in both its therapeutic and 
neurotoxic effects, including direct effects on intracranial endothelial cells and brain 
white matter, as well as immunologic mechanism.
9 
A spectrum of clinical syndromes 
may occur: radionecrosis, necrotizing leukoencephalopathy, mineralizing 
microangiopathy with dystrophic calcification, cerebellar sclerosis and spinal cord 
dysfunction. Neuropsychological and neuroendocrinological damage are the most 
common categories of outcome/sequelae.
9
 There is also increasing evidence that children 
that undergo cancer treatment and become long-term survivors, may be at increased risk 
for the development of secondary CNS tumors, possibly as a result of the aforementioned 
treatment.
9
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Side Effects 
Many side effects manifest during, and after, the treatment of cancer in children, 
and can be both psychological and physical. At the time of diagnosis, and upon the 
advent of treatment, certain symptoms appear to be comparably more prevalent. They are 
also seen as a greater burden, though this burden decreases through the course of 
recovery.
10 
The symptoms reported as the most problematic during treatment are: 
emotional distress, fatigue, nutrition, and pain; the latter often being described as the 
worst.
10
 Some less prevalent, but still distressing, symptoms include: difficulty breathing, 
swallowing, and difficulty with urination.
10
 Fatigue, one of the more prevalent symptoms, 
has been found to interfere with child development,
11
 as it can severely limit activity 
during treatment (however, this may be reduced with therapy). 
Physical activity in survivors of childhood cancer is an area that has received 
more attention in recent research. A survivor of childhood cancer may be limited in their 
physical activity (walking, jumping, reaching, bending) secondary to neurological and 
musculoskeletal deficits.
12, 13
 Although a child may attempt to resume a normal amount 
of physical activity, they will likely have difficulties keeping pace with same aged peers 
without a cancer diagnosis. Hoffman et al. compared the physical performance of 
survivors of childhood cancers to the siblings of the survivors and found similar levels of 
activity in each group. However, the survivors performed at a lower ability than the 
siblings of the survivors.
12
 This is pertinent because the result of this decreased quality of 
performance may lead to decreased leisure physical activity. For example compared to 
controls, adult survivors of childhood ALL reported less leisure time physical activity.
8
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The attempt at increasing physical activity may improve a patient’s quality of life, 
but it is not enough to overcome all of the physiological changes that occur with intense 
chemotherapy and long term hospitalization from cancer.
12
 For example, children with 
ALL often present with decreased balance compared to age-matched control subjects.
8
 
Balance dysfunction is not the only impairment present after intense chemotherapy; 
survivors of cancer may also demonstrate poor mobility, decreased sensation, decreased 
endurance, and growth failure due to the decreased production of growth hormones.
14,15
  
Side effects from cancer and treatment of cancer do not end after a patient goes 
into remission. Many individuals have long term residual side effects from both the 
cancer and the intense treatment. Children are at greater risk for side effects from cancer 
therapy because the treatment tends to target rapidly growing cells.
13
 In a 2010 study by 
Haddy and Haddy, 75% of participants with pediatric cancer survivors had one or more 
late side effects.
15
 This finding is consistent with an investigation by Hoffman et al. in 
which two-thirds of long-term cancer survivors presented with at least one chronic 
condition.
12
 These include: respiratory symptoms, changes in liver function, 
hyperglycemia, hypothyroidism, and altered renal functioning.
15
 
Furthermore, survivors of childhood cancers can be at greater risk for many types 
of conditions and deficiencies. These include, but are not limited to: early mortality, 
second malignancies, immune system suppression, infectious disease, endocrine 
deficiencies, cardiac impairments, pulmonary dysfunction, sensory loss, gastrointestinal 
problems, neurocognitive deficits, genitourinary disorders, musculoskeletal 
abnormalities, and infertility.
13
 Any of these subsequent side effects and risk factors can 
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lead to secondary limitations including lack of educational attainment, impaired 
emotional well-being, and reduced physical performance. Ultimately, this may affect a 
child’s daily routine, school attendance, and/or interpersonal relationships.
13
 
A 2011 study published in Oncology Nursing Forum examined improvement of 
the 6 Minute Walk Test (6MWT) in pediatric patients with ALL, lymphoma, or solid 
tumor during chemotherapy treatment. The study found that those with ALL had the 
greatest improvement on the 6MWT compared to those with lymphoma or solid tumors.
11
 
Although patients with ALL showed the most improvement on the 6MWT, these patients 
also reported more fatigue, pain, and insomnia, overall when compared to patients with 
other hematological malignancy (e.g. AML). Patients with ALL have also been found to 
have lower quality of life, physical function, and cognitive function than patients with 
AML.
4
 
In addition to physical side effects, psychological symptoms are often common 
during treatment due to the initial shock of diagnosis and the burden of being treated for 
cancer. Patients receiving treatment for hematological malignancies are subjected to 
increased frequency of anxiety and depression, though both are often undetected.
4
 Other 
psychological problems include: fear, uncertainty, as well as mood and cognitive issues.
16
 
The latter can be present in both older and younger patients, but they are not as severe as 
the emotional symptoms that may be present.
4
 
 
Chemotherapy-Induced Peripheral Neuropathy 
The effects of chemotherapy treatment for childhood cancers may lead to a 
number of unfortunate side effects, as previously described. One of the potentially most 
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devastating effects is the changes that result in the peripheral nervous system. 
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting 
neuropathy defined as, “Any injury, inflammation or degeneration of the peripheral 
nerves because of the administration of a chemotherapeutic agent.”
3
 CIPN can be 
manifested in any of the three functional divisions of the nervous system: sensory, motor, 
and autonomic nerves resulting in damage within and around the neuron. It can occur at 
the axon, cell body, and myelin level.
17
 The mechanism of damage and symptoms that 
occur depend on the type of nerve affected and specific chemotherapeutic agent used. 
Commonly used neurotoxic agents causing damage to nerve fibers include, but are not 
limited to: platinum-based compounds, vincristine and vinca alkaloids, taxanes, 
epothilones, bortezomib, and thalidomide.
19, 3
 
Within the nervous system, two types of peripheral nerve fibers exist, small and 
large. Motor axons are large fibers, myelinated, fast conducting, and directly control 
muscles. Typically, these motor neurons have the ability to reinnervate and sprout in 
order to survive the effects of chemotherapeutic agents, thereby resulting in more mild 
symptoms and less frequent occurrence.
16
 Sensory and autonomic axons are characterized 
by small fiber nerves, unmyelinated, slower conduction, and sense pain, temperature, and 
control autonomic function. The cell bodies of these peripheral sensory neurons lie in the 
dorsal root ganglion (DRG), outside the protective blood-brain barrier, thereby leading to 
an increased vulnerability for damage from chemotherapeutic agents. Also, the DRG is 
highly vascularized, being supplied by a large number of capillaries, thereby increasing 
the permeability for toxic compounds.
16
 
 
 
9 
 
Therefore, CIPN has been shown to first manifest in small sensory fibers leading 
to changes in sensation, paresthesia, dysesthesia, cold sensitivity, tingling, numbness, 
proprioception, vibration, and reflex changes.
20
 It occurs in a length dependent manner, 
affecting the longest axons first and spreading proximally, also known as a “stocking and 
glove pattern.”
17,16
 A possible explanation for this distribution has attributed the effect to 
longer fibers having greater surface area; thereby putting these fibers at greater risk of 
exposure to harmful agents.
16
 
CIPN has been shown to be dose dependent, relating to the administration of the 
drug and schedule of delivery (occurring within hours, days, or weeks), with the 
exception of cisplatin where symptoms may occur months after drug administration 
(coasting effect). A number of risk factors have also been identified increasing the risk 
for CIPN, including: heritable factors, personal, multidrug/multimodal use, radiation, and 
certain diseases (vitamin B12 deficiency, diabetes, hypothyroidism, and paraneoplastic 
diseases).
19
 Although risk factors have been stated and the detrimental effects of 
chemotherapeutic agents noted, chemotherapy continues to the frequently used in the 
treatment of childhood cancers.  
 
PT Implications 
Although childhood cancer mortality rates have decreased, which can be 
contributed to multimodal improved therapy, a number of short-term and long-term 
effects are still reported.
18
 These effects can be detrimental to children as they develop, in 
turn impacting a child and family’s quality of life, risking functional decline, and 
additional health related complications.
12 
A comprehensive understanding about patient’s 
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symptoms is necessary for management. As stated previously, “two-thirds of long term 
survivors will develop ≥ 1 chronic condition related to prior therapy.”
12
 It is critical for 
health care providers to acknowledge the symptoms children with cancer are 
experiencing. Research has begun to improve symptoms in those receiving 
chemotherapy, but it has been structured towards chemotherapy-related nausea and 
vomiting.
12
 As previously noted, these symptoms are not the only chemotherapy side 
effects children are experiencing.  
Physical therapy (PT) can play a role in providing rehabilitative services to help 
with improving function, adapting needs, finding compensatory strategies, and managing 
structural and functional losses related to disease processes.
19 
 Unfortunately, little 
research has been done to show the effects it may have on children receiving 
chemotherapy for childhood cancers.
19
 Montgomery et al. looked at 5+ year survivors 
from the Childhood Cancer Survivor Study (CCSS) addressing the use of PT and 
chiropractic services and association with health-related quality-of-life (HRQL). They 
compared PT and/or chiropractic utilization between survivors and siblings, and by 
diagnosis, treatment and demographic characteristics; associations between chronic 
disease, PT/chiropractic use, and HRQL.
19
 Their results showed a slightly higher 
percentage of survivors reported using chiropractic (12.4%) than PT (9.2%) services, yet 
both are minimally utilized. 
This is interesting to note, as many children receiving chemotherapy treatment 
show both short and long term effects potentially limiting their physical function. A 
poorer HRQL measure was also noted in those who used PT/chiropractic services. They 
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attributed this to the possibility that survivors with more severe late effects may utilize 
services more in comparison to those with less effects, in turn reporting a poorer 
HRQL.
19
 However, it is important to note that these results cannot be generalized to all 
children with childhood cancer. This study has offered good insight into how many 
additional services are utilized, or underutilized, and the role PT can play in optimizing 
physical function.  
In light of current underutilization, it is important to educate patients on the role 
PT can have in treating children with childhood cancers. Neuropathy is a common side 
effect of chemotherapeutic agents used for treatment of childhood cancers. Specifically, 
CIPN is the most widely reported and has been the focus of research efforts. However, 
effective management of symptoms can be difficult to approach as a result of the broadly 
described symptoms and neurotoxic effects across studies.
16
 Therefore, the National 
Comprehensive Cancer Network (NCCN) task force created an outlining of 
recommendations for the possible prevention, diagnosis, and management of 
neuropathy.
16
 
Treatment starts with evaluating patients. Evaluations should be done at baseline, 
throughout and following the course of treatment. It involves subjective and objective 
measures; however, no gold standard has been established for CIPN. The lack in 
consistency in rating and patient reported symptoms adds to the difficulty of treating 
CIPN. Objective measures include EMG, nerve conduction, quantitative sensory tests, 
and other additional imaging techniques, but these have shown poor correlation with 
subjective reports by patients.
16 
History and physical examination should also be included 
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to account for possible exposures impacting the patients functioning. A combination of 
symptom characteristics, past medical history, associated comorbidities, and detailed 
description of dosing regimen should all considered. Specifically for the physical exam, 
the NCCN recommends, “assessment of sensory abnormalities, deep tendon reflex 
dysfunction, motor weakness, pain characteristics, autonomic symptoms, and most 
importantly, functional impairment.”
16
 Finally, a number of physician based grading 
systems and patient-based instruments have been developed to determine severity of 
neuropathic symptoms. The NCCN outlines a number of additional recommendations for 
health care providers while treating CIPN: constant assessment, pain assessment tools, 
questions based around ADLs, and referral to specialist if needed.  
Unfortunately there is no single treatment option specifically for CIPN, therefore, 
treatment typically includes managing symptoms with protective agents, TENS, and 
complementary alternative medicine. In a randomized control trial, Mokhtar et al. 
attempted to determine the effectiveness of glutamic acid in reducing neurotoxicity of 
vincristine, as it had been shown to modify the effects in preclinical animal trials. The 
following effects were used to measure toxicity: achilles and patellar tendon reflexes, 
paresthesia, and increased frequency of constipation.
7
 The onset of neurotoxicity was 
much later in the glutamic acid group compared to the placebo group, but further research 
is needed to help determine the efficacy of toxicity-reducing co-treatments. 
The NCCN also outlined the role PTs can play; PT intervention can assist with 
managing functional deficits including balance, strength, sensory loss, and performing 
ADLs. Balance activities can begin with static standing and moving to advance 
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manipulation of objects done statically and dynamically. Manipulation of activities can 
be done by masking visual input, changing size of objects, changing speed of activities 
done, and changing surfaces. Daily strengthening programs can be established to improve 
lower extremity strength, gait training, reduce fall risk, and assist with ADLs. These 
programs have shown beneficial results for improving strength.
16
 
Gait training specifically should include observation of footwear, gait deformities, 
balance ability, strength, endurance, and how patients respond in complex conditions. 
The NCCN reports benefits of training with bodyweight support systems as well.
16
 
Overall, therapeutic interventions need to be focused on the patient as a whole. Due to the 
many adverse events that may occur throughout treatment, it is important to understand 
the causes for decline in function may be due to multiple variables. Education, advice, 
coping strategies, modifications, adaptive equipment, and safety are all areas 
recommended to be discussed with patients throughout their treatment process.
16
 
Hoffman et al. found similar results when they compared the physical 
performance of children with childhood cancers to their siblings. Physical performance 
was measured by using a handheld dynamometer, 6 min walk, and TUG. Their results 
showed that even though children with childhood cancer had poorer results on 
performance measures, they participated in regular physical activity as much as their 
siblings.
12
 In light of this, further referral may be necessary for these patients, for 
assessment of physical function and continued exercise programs, which can promote an 
active lifestyle and prevent ongoing decline.  
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Purpose of Study 
As previously stated, pediatric cancer is a highly prevalent disease, with a 
growing survival rate, due to rapidly evolving treatment techniques. However, with 
chemotherapy being essential to treatment, CIPN is unfortunately a common 
consequence, with effects ranging from discomfort to severe debilitation. We do know 
that the effects of CIPN may continue to influence a child’s quality of life long after the 
treatment of their cancer. It is also apparent that the severity and frequency of adverse 
events heavily depend on dose, duration, schedule of administration, cumulative effects 
of additional drugs, and preexisting dysfunction.
16 
Yet despite high overall occurrence, 
data on neuropathic toxicity appears fragmented and there has not been a research focus 
on chemotherapeutic medicine.
16
 
Most of the existing research lies in the adult population, which though it may be 
informative as to the late effects, ignores that treatment combinations (including 
medication types and dosage) may differ in pediatric populations and lead to different 
impact on the nervous system. There also appears to be a lack of evidence in regard to 
standardization of reporting CIPN-like symptoms; it may be difficult for a school age 
child to report their symptoms. As an example of the gaps in current literature, Ness et al. 
provided evidence of chemotherapy-related neuropathic symptoms and functional 
impairment in adult survivors. 21 out of 531 participants tested positive for both motor 
(17.5%) and sensory (20%) impairments and demonstrated functional impairment in 
6MW, TUG, and SOT.
13 
However, they failed to provide description of PT throughout 
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the course of chemotherapeutic treatment, and the information is only very broadly 
applicable to a pediatric population, if at all. 
A feasible measure of CIPN has been created; the mTNS, which demonstrates 
greater sensitivity than other existing measures.
8
 However, more research is needed 
utilizing this tool in order to create normative values and cut off scores in order to be 
used as a clinical measure of CIPN symptoms.
8
 Further research is also needed when 
looking at the effects of chemotherapy and peripheral neuropathies in pediatric cancers 
longitudinally. It needs to start at diagnosis and be observed throughout the course of 
treatment.
14
 In addition, it would be beneficial to know what mechanisms are directly 
responsible for these effects, and what interventions can be implemented for the 
treatment of CIPN.  
Therefore, the key purpose of our study is to evaluate the trajectory of recovery 
for CIPN at three and six months post-treatment, in children with ALL, lymphoma, and 
non-CNS solid tumors. As previously mentioned, brain tumor diagnoses were excluded 
as they present with their own unique deficits that could potentially confound our 
research. Our secondary aim was to evaluate and quantify the recovery of balance and 
manual dexterity post-treatment. Finally, we wanted to identify if there were any 
significant differences between diagnostic groups. 
 
Outcome Measures 
The most common outcome measure used clinically for children and adolescents 
with CIPN is the Common Terminology Criteria for Adverse Events (CTCAE).
21
 
CTCAE objectively measures adverse events that occur after cancer treatment in 26 
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different body systems. Sensory and motor neuropathy is used to measure the severity of 
CIPN.
21  
Recent evidence has shown that there are limitations to the CTCAE when 
determining CIPN. For example, the CTCAE is less sensitive to small changes in reflexes 
because it only measures the deep tendon reflex of the ankle, rather than both the ankle 
and the knee. It also does not measure a wide range of large and small diameter sensory 
fibers, resulting in misleading information about the severity of CIPN.
12
 The limited 
range of sensory fiber sizes tested with the CTCAE inspired the search for a better-
equipped outcome measure for the assessment of CIPN. 
An alternative test used in the past is the Total Neuropathy Score (TNS), which 
was initially developed for assessing peripheral neuropathy in adults with diabetes.
12, 13
 
The TNS includes subjective and objective information about sensory, motor, and 
autonomic symptoms which may be present.
12
 For the upper and lower extremities, pin 
sensation is assessed via a Medipin and vibration sense via a Biothesiometer. Motor 
function is objectively measured via strength testing of the great toe extensors, ankle 
dorsiflexors, finger abductors, and wrist extensors. The achilles and patellar deep tendon 
reflexes are also assessed.
12
 Autonomic symptoms are subjectively measured through 
questions in the patient interview. 
The TNS has been found to be reliable (interrater=0.94; intrarater=0.97) and valid 
for adults, however, changes were required prior to using the tool for children and 
adolescents.
12,13
 In order to collect subjective information regarding symptomatology, the 
patient interview was altered to be read aloud  to the children and the language was 
simplified. Furthermore, the scoring rubric was evaluated and deemed appropriate by 
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neurologists, experts of clinical practice of oncology, and pediatric physical therapists. 
The new variation of the TNS for children being treated for pediatric cancer is called the 
Pediatric Modified Total Neuropathy Score (peds-mTNS). The entire peds-mTNS, 
patient interview and five part neurological exam, takes about ten minutes.
12 
 
In order to assess the peds-mTNS more thoroughly, a pilot study was conducted 
by Gilchrist et al. in 2009. The study, published in Rehabilitation Oncology, evaluated 
the performance of the peds-mTNS by 20 participants diagnosed with leukemia, 
lymphoma, or solid tumors. Specific findings of this study helped to direct and validate 
the development of the peds-mTNS. For example, during the interview, 15 of the 20 
reported either a sensory or motor symptom, or both. Although the most prevalent 
symptom was sensory deficits, objective information from pin and vibration sensitivity 
did not correlate with the subjective sensory findings. Additionally, neither pin sensitivity 
nor vibration sensitivity correlated with one another, indicating that each of those are 
independent variables which need to be included within the peds-mTNS. It is important 
to note that neither ceiling nor floor effects were found when using the peds-mTNS. Two 
limitations of the peds-mTNS are that autonomic neuropathy, which includes 
thermoregulation, digestion, and orthostatic hypotension, is not assessed objectively. The 
second limitation is peds-mTNS is not appropriate for children younger than five years 
old.  
The peds-mTNS has been shown to be more valid and reliable than the CTCAE. 
The sensory clinical exam in the peds-mTNS includes assessment of both small diameter 
fibers. Small fiber testing is accomplished via the pin sensibility portion of the 
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neurological exam, and large diameter fibers by the vibration and deep tendon reflex 
portion of the outcome measure. The CTCAE does not include the same wide of range of 
fiber size tested.
12 
The CTCAE and the peds-mTNS were compared by Gilchrist et al. in 
2013. This study demonstrated that the CTCAE failed to detect light touch deficits in 
40% of the participants, vibration sensory deficits in 20%, and was incorrect in the 15% 
of the population who reported that motor neuropathy deficits were not present. The 
CTCAE also had a low sensitivity of .2. When directly comparing the peds-mTNS and 
CTCAE, there was no correlation between any of the components, except for strength 
scores. The study suggests that the Peds-mTNS is more sensitive than the CTCAE at 
detecting CIPN. 
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Chapter II: Methods 
Subjects 
All subjects were approached for participation in the study while at outpatient 
appointments at a children’s oncology clinic. Inclusion criteria were children ages 5 to 18 
years old, a new diagnosis of leukemia, lymphoma or solid tumor (Wilms', 
Rhabdomyosarcoma, neuroblastoma), receiving chemotherapy treatment using 
Vincristine or Cisplatin, English-speaking subject and guardian, and viewed as 
appropriate for study by their physician, nurse or physical therapist. Exclusion criteria 
were previous cancer diagnosis or relapse, CNS tumor, developmental or other 
neuromuscular disorder, non-English speaking subject or guardian, and upper or lower 
extremity amputations or limb deficiency. 
The institutional review board at Children’s Hospitals and Clinic of Minnesota 
reviewed the recruitment material, consent forms, and testing procedures for the study. 
Parents of each subject completed a demographic questionnaire that includes questions 
about age, sex, racial background, and past medical history. A trained clinical research 
associate extracted information about cancer diagnosis and treatment from medical 
records. This information included: diagnosis and staging, surgical interventions, 
cumulative dose of each chemotherapeutic agent used, radiation treatments, and 
comorbid conditions. 
 
Timing of measures 
All subjects underwent the same testing procedures at 3 time points. Measures 
were completed during treatment, a minimum of 2 months after the start of 
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chemotherapy, at a time when their symptoms were anticipated to be at their peak. 
Specifically, children with ALL were tested at the end of the “delayed intensification” 
phase of their treatment, approximately 6 months into treatment. All other groups were 
tested between 2-3 months after the initiation of treatment. Data was again collected at 3 
months and 6 months from the end of chemotherapy treatment to investigate recovery of 
nerve function. Subjects, who had a relapse of their cancer and required additional 
treatment, were excluded from the study. Therefore, subjects did not receive any 
treatment from the 3 month to 6 month measures. 
 
Ped-mTNS 
A clinical outcome measure for CIPN is the Total Neuropathy Score (TNS). This 
was initially developed for assessing peripheral neuropathy in adults with diabetes. The 
Pediatric Modified Total Neuropathy Score is a modified version of the TNS adapted for 
use in children and adolescents undergoing cancer treatment.  This measure has 
demonstrated reliability and validity and thus was the measurement of choice for our 
study when looking at the effects of CIPN in school-aged children with cancer.
20
 
 
Bruininks-Oseretsky Test of Motor Proficiency, Version 2 (BOT-2) 
In addition to the 8 item Peds-mTNS measure, each subject additionally 
underwent the balance and manual dexterity subscales of the Bruininks-Oseretsky Test of 
Motor Proficiency, version 2. Both subtests were administered according to standardized 
protocols. The BOT-2 is designed to assess motor proficiency in children with mild to 
moderate functional deficits. Age and gender based scores are established for each 
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subtest and each age category. The standardized mean score is 15 points with 
standardized deviation of 5. Both the balance and manual dexterity subtests have Inter-
rater reliabilities above 0.9.
22 
 
Data Analysis 
 
SPSS Software was used for data analysis. Descriptive statistics was evaluated for 
all subject demographics. A one-way repeated measures ANOVA was run to compare all 
subjects over time. Effect size was evaluated by determining the Partial Eta Squared. A 2-
way repeated measures ANOVA was run to compare mean Peds m-TNS total scores for 
each diagnostic group over time. A significant difference was indicated by a p value < .05 
for all ANOVA data analysis. And finally, calculations were done to see the frequency of 
normal vs. abnormal scores for the Peds-mTNS total score, each sub-category, manual 
dexterity, and balance. 
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Chapter III: Results 
There were a total of 47 subjects with 53.2% of the subjects being female. The 
participants in the study ranged from 5 to 18 eighteen years old and had a mean age of 
11.1+/-4.099 years old. Time in treatment ranged from 57 to 512 days with a mean of 
151.7 days +/- 100.1. (Table 1) 
 
Table 1. Descriptive Statistics and Subject Demographics 
 Mean Standard Deviation Range 
Sex Male (n=22) 
Female (n=25) 
- - 
Age (years) 11.1 4.099 5-18 
Weight (kg) 45.3 24.6 16.1-141.6 
Height (cm) 144.4 27.5 40.6-196.9 
BMI 
(percentile score) 
56.98 30.5 1-99 
Time in Treatment 
(days) 
151.7 100.1 57-512 
 
A majority of the subjects were diagnosed with ALL at 38%, followed by 
Hodgkin’s lymphoma (30%), Wilms' tumor (17%) and other non-CNS solid tumors 
(15%). All of the subjects in the study received vincristine. Twenty-two subjects received 
both vincristine and IT methotrexate. There were a total of twenty-five subjects that only 
received vincristine for treatment. There were no subjects in the study that only received 
IT methotrexate for chemotherapeutic treatment.  
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A one-way repeated measures ANOVA was run in order to determine the 
significant change in mean Peds-mTNS scores over time. Figure 1 depicts the decrease in 
Peds-mTNS mean scores over time.  Across all subjects, the mean scores significantly 
decreased between each measurement with a p value of < 0.001. The bolded black line 
indicates a normal score of less than 5; lower scores demonstrate less peripheral 
neuropathy. Therefore, at 6 months the mean score was below 5 indicating a score within 
normal limits. The overall effect size was found to be large at 0.609.   
 
Figure 1. Change in Peds-mTNS Mean Scores Over Time 
 
A pairwise comparison was run to find where significant differences (p < 0.05) 
occurred in the separate categories within the Peds-mTNS over time. From “On 
Treatment to 6 months” there was a significant difference within: motor symptoms, 
autonomic symptoms, right and left dorsiflexion strength, right and left great toe strength, 
and deep tendon reflex.  From “3 months to 6 months” there was a significant difference 
within: lower extremity vibration, and right and left dorsiflexion strength. It was noted 
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that right and left dorsiflexion strength had a significant change in mean scores over both 
time period. Whereas, there were no significant changes in mean scores for lower 
extremity vibration until after 3 months post-treatment.  
Table 2 shows the percentage of subjects with deficits on treatment, 3 months, 
and/or 6 months post-treatment. Each subscale of the Peds-mTNS total scores, BOT-2 
Balance, BOT-2 Manual Dexterity, and the subjective/clinical items of the Peds-mTNS 
are included. There was the greatest percentage of subjects with deficits at 6 months on 
the BOT-2 Balance (81.1%). There were also relatively high remaining percentage of 
subjects with deficits at 6 months with the Peds-mTNS Total scores (37%) and BOT-2 
Manual Dexterity Scores (46.7%). The categories of the Peds-mTNS with the largest 
percentage of subjects with deficits at 6 months include: left and right great toe strength 
which were 54.3% and 63% respectively, and deep tendon reflexes at 52.2%.  
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Table 2: Percentage of Subjects with Deficits and Group Means at On Treatment, 3 
months post-treatment, and 6 months post-treatment. 
Ped-mTNS  
Items 
On Treatment 3 Month 6 Month 
% with 
Deficit 
Group 
Mean 
% with 
Deficit 
Group 
Mean 
% with 
Deficit 
Group 
Mean 
Ped-mTNS Score 87.0 9.49 53.2 5.81 37.0 4.24 
BOT-2 Manual 
Dexterity 
84.4 10.4 58.7 13.54 46.7 14.76 
BOT-2 Balance 95.7 7.72 89.4 9.21 81.1 10.75 
Subjective Symptoms 
Sensory  29.8 0.38 17.0 0.26 10.9 0.15 
Motor/Functional  55.3 0.98 23.4 0.36 23.9 0.3 
Autonomic 47.8 0.96 28.2 0.45 26.7 0.43 
Clinical Examination 
Light Touch UE 17.4 0.37 6.5 0.09 4.3 0.04 
Light Touch LE 34.0 0.85 21.3 0.55 17.8 0.59 
Pin Sensibility 46.8 0.51 44.7 0.51 33.3 0.38 
Vibration UE 4.3 0.11 0 0 0 0 
Vibration LE 30.0 0.68 25.5 0.7 8.7 0.28 
Strength Great Toe L 89.4 1.68 61.7 0.96 54.3 0.67 
Strength Great Toe R 89.4 1.79 74.5 1.09 63.0 0.83 
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The mean scores of the peds-mTNS for each diagnostic group decreased over 
time. The mean scores for subjects with Wilma’ tumor and Hodgkin’s lymphoma 
remained above the population norm indicating neuropathy. A two-way repeated 
measures ANOVA revealed a significant difference between means scores of ALL and 
Hodgkin’s lymphoma with a p value of <0.05. Figure 2 depicts the change in subject 
mean scores on the Peds-mTNS over time by diagnosis. The black line on the graph 
indicates an abnormal Ped-mTNS score which is greater or equal to 5.  
 
Figure 2. Change in Peds-mTNS Scores Over Time Per Diagnosis 
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Figure 3 is similar to Figure 2 however it displays the change in manual dexterity 
over time for each diagnostic group. The bolded black line once again shows the 
population norm score, which is 15. Therefore, those with other non-CNS tumors 
achieved a mean score above the population norm at 6 months post treatment. All other 
diagnostic groups improved over time however did not reach the population norm. A two 
way repeated measures ANOVA did not find any significant difference between 
diagnostic groups in regard to change in manual dexterity outcome measure scores. 
 
Figure 3. Change in BOT-2 Manual Dexterity Scores Over Time by Diagnostic Group 
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None of the diagnostic groups reached the normative value (15) on the BOT-2 
balance subscale however, each group’s mean scores improved over time. Those with 
ALL had the lowest mean score of 9.82 at 6 months. A two way repeated measures 
ANOVA detected no significant difference in BOT-2 balance score changes over time 
and between diagnostic groups. (Figure 4) 
 
Figure 4. Change in BOT-2 Balance Scores Over Time by Diagnostic Group 
 
In order to see what variables could have affected the subjects trajectory of 
recovery we looked at mean age, time in treatment, type of chemotherapeutic medication, 
and the cumulative dose of those medications per diagnosis. Subjects with Hodgkins 
lymphoma had the highest mean age (14.46+/-4.08) and those with Wilma’ tumor had the 
youngest(7.5+/-2.20). Subjects with ALL had the greatest mean time in treatment at 
802.5+/-410.96 days. The next closest mean time in treatment was the mean score for 
subjects other non-CNS tumors at 172.71+/-40.55 days.  
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All subjects with ALL received both types of medication. These patients also 
received the greatest cumulative dose of both medications. Those diagnosed with Wilma’ 
tumor and Hodgkins lymphoma only received vincristine. Within the subjects that were 
diagnosed with another non-CNS tumor, 4 subjects received only vincristine and 3 
subjects received both types of chemotherapeutic agents. (Table 3) 
Table 3: Descriptive data of mean age and treatment protocol for each diagnostic group.  
Diagnosis Mean 
Age 
(SD) 
Days in 
Treatment 
(SD) 
Vincristine Cumulative 
Amount 
(SD) 
IT Meth Cumulative 
Amount 
(SD) 
ALL 9.83 
(3.45) 
802.5 (410.96) 53.36 (11.56) 237.83 (70.27) 
Wilma’ 
Tumor 
7.5 (2.20) 157.38 (50.57) 21.17(4.23) 0 
Hodgkins 14.46 
(4.08) 
104.58 (63.16) 10.09 (1.97) 0 
Other 12.29 
(2.69) 
172.71(40.55) 11.93 (8.66) 53.57 (69.20) 
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Chapter IV: Discussion 
Based on the results this study shows all group mean scores decreased 
significantly on the Peds-mTNS over the three data collection periods, indicating a 
decrease in peripheral neuropathy (Figure 4). However, it should be noted at 6 months 
post-treatment, 37% of subjects still presented with deficits on the Peds-mTNS (Table 2). 
Of those 37%, the areas of greatest deficits were found in bilateral great toe extension 
strength and deep tendon reflexes. When comparing the BOT-2 scores at 6 months 
deficits in balance (Figure 6) and manual dexterity (Figure 5) were identified. The 
deficits in balance, manual dexterity, deep tendon reflex and great toe extension strength 
could be indicative of greater residual loss to the motor system. 
Table 4: Peds-mTNS data of current research subjects compared to normative values 
from a 2013 research study by Gilchrist and Tanner 
20
 
Peds-mTNS Item Subjects (n=47) Controls (n=41) 
Sensory Symptoms 0.15 0.02 
Motor Function 0.30 0.10 
Autonomic Symptoms 0.43 0.46 
Light Touch 0.59 0.05 
Pin Sensation 0.38 0.32 
Vibration Sensation 0.28 0.10 
Distal Strength 0.83 0.39 
Deep Tendon Reflex 1.20 0.00 
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The 2013 study by Gilchrist and Tanner was used to reference normative values 
for the Peds-mTNS.
20
 It was found that the subject groups scored greater for every single 
item except for autonomic symptoms as seen in (Table 4). .  Interestingly, deep tendon 
reflex scores were found to have the greatest difference between the subjects and the 
control groups.  
When comparing across diagnostic groups for Peds-mTNS, scores for subjects 
with ALL and other non-CNS tumors were within normal limits at 6 months (Figure 2), 
indicating significant decrease in peripheral neuropathy. Those with other non-CNS 
tumors also had a BOT-2 manual dexterity mean score that was greater than population 
norms at 6 months post treatment (Figure 3).  Indicating, the average subject in this 
diagnostic group was able to recover manual dexterityl. This differs from the BOT-2 
balance scores, where none of the diagnostic groups had a mean score that reached the 
population norm. With this being said subjects with ALL had the best mean score at 6 
months post-treatment for the Peds-mTNS, however they did not recover well on the 
BOT-2 balance outcome measure. Relative lack of recovery could be indicative of greater 
deficits in the CNS due to greater time in treatment, large cumulative dose of 
chemotherapeutic drugs, and the use of both, vincristine and IT methotrexate. IT 
methotrexate has greater potential for chemotoxic effects on the CNS due its ability to 
cross the blood-brain barrier.
23
  
When comparing across all the diagnostic groups (Figure 2), ALL and Hodgkin’s 
lymphoma showed statistically significant differences for Peds-mTNS mean scores over 
time. Subjects with ALL improved significantly more than those with Hodgkin’s 
 
 
32 
 
lymphoma. This finding was inconsistent with expectations, as the ALL group received 
higher doses, multiple medications, and were on treatment far longer, as shown in (Table 
3) in the results section. When examining other differences between ALL and Hodgkin’s 
lymphoma, age differences were notable, with the ALL group being significantly 
younger than the Hodgkin’s group. This correlation leads us to hypothesize that age-
dependent neuroplasticity may play a role in the recovery from CIPN. 
As stated previously research shows “⅔ of long term survivors will develop at 
least one chronic condition related to prior therapy.”
l
 Based on our results, balance and 
manual dexterity were affected during treatment, but balance deficits more commonly 
persist after treatment is complete. It is important to note that patients with non-CNS 
cancers may present with deficits in the aforementioned areas and these deficits may 
carry over into their remission and long-term recovery, which in turn may affect their 
continued quality of life.
24
 Physical therapy can play a role in providing rehabilitative 
services to help with improving function, adapting needs, finding compensatory 
strategies, and managing structural and functional losses related to disease processes.
s
 
This study had both strengths and limitations. A strength to the study is the 
relatively large number of subjects allowing a more reliable reflection of the subject 
population. The Peds-mTNS has been shown to be a valid and reliable instrument for 
assessing peripheral neuropathy in this subject population. A potential limitation was that 
data transfer to SPSS software had potential for increased errors. In order to reduce this 
risk, random spot checks were performed through data entry. Subject availability and the 
lack of controls in this study are also weaknesses. 
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Chapter V: Conclusion  
The current literature on CIPN in this subject population states: “motor cells 
recover faster than sensory cells”.
16
  However, our study demonstrated that a greater 
percentage of subjects continued to have significant motor deficits at 6 months when 
compared to sensory symptoms. While we have discussed what we believe to be a likely 
course for CIPN and recovery. Other factors need to be considered as they may have 
affected subjects’ severity of symptoms. Much of the current research has been on 
patients with ALL. However, our data shows that ALL subjects had the most successful 
recovery, and therefore it follows that patients with Hodgkin’s lymphoma may benefit 
more from a focus of future research. The potential long-term side effects of CIPN in the 
pediatric population can be diminished with skilled physical therapy interventions that 
are researched based and individually focused. 
  
 
 
34 
 
References 
 
1. National Cancer Institute. Childhood Cancers. National Cancer Institute. (1-10-
2008). Avalible at:  http://www.cancer.gov/cancertopics/factsheet/Sites-
Types/childhood Accessed 10-10-2013.  
2. American Cancer Society. Learn About Cancer. American Cancer Society.  
Avalable at: 
http://www.cancer.org/cancer/leukemiainchildren/detailedguide/childhood-
leukemia-key-statistics Accessed 10-24-2013. 
3. American Childhood Cancer Organization. Childhood Cancer Statistics. 
American Childhood Cancer Organization.   Available at: 
http://www.childrenscancer.org/main/acute_lymphoblastic_leukemia_all/ 
Accessed 10-24-2013. 
4. Zareifar S, Farahmadfar R, Cohan N, Modarresnia F, Haghpanah S. Evaluation of 
health related quality of life in 6-18 years old patients with acute leukemia during 
chemotherapy. Indian J Pediatr. February 2012; 79(2):177-182. 
5. Medline Plus - Vincristine Injection. Available at: 
http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682822.html. Accessed 
November 9, 2013. 
6. Salman M, Khoury NJ, Khalifeh I, et al. Congenital infantile fibrosarcoma: 
Association with bleeding diathesis. Am J Case Rep. 2013;14:481-485. 
7. Mokhtar GM, Shaaban SY, Elbarbary NS, Fayed WA. A trial to assess the 
efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in 
 
 
35 
 
pediatric malignancies: a pilot study. J Pediatr Hematol Oncol. 2010;32(8):594-
600. 
8. Gilchrist L, Tanner L, Hooke M. Measuring chemotherapy-induced peripheral 
neuropathy in children: development of the ped-mTNS and pilot study results. 
Rehabilitation Oncology. 2009; 27(3)7-15. 
9. Packer RJ, Meadows AT, Rorke LB, Goldwein JL, D'Angio G. Long-term 
sequelae of cancer treatment on the central nervous system in childhood. Med 
Pediatr Oncol. 1987;15(5):241-53. 
10. Poder U, Ljungman G, Von Essen L. Parents’ perception of their children’s 
cancer-related symptoms during treatment: a prospective, longitudinal study. J of 
Pain and Symptom Management. 2011; 40(5): 661-670. 
11. Hooke M, Garwick A, Gross C. Fatigue and physical performance in children and 
adolescents receiving chemotherapy. Oncology Nursing Forum. November 2011; 
38(6):649-657. 
12. Hoffman M et. al. Deficits in physical function Among young childhood cancer 
survivors. Journal of Clinical Oncology. August 2013; 31:2799-2805. 
13. Ness K and Gurney J. Adverse late effects of childhood cancer and its treatment 
on health and performance. Annual Review of Public Health. 2007; 28:279-302. 
14. Ness K et. al. Chemotherapy-related neuropathic symptoms and functional 
impairment in adult survivors of extracranial solid tumors of childhood: results 
from the st. jude lifetime cohort study. Archives of Physical Medicine and 
Rehabilitation. 2013; 94:1451-7. 
 
 
36 
 
15. Haddy R and Haddy T. Lifetime follow-up care after childhood cancer. J of 
American Board Family Medicine. 2010; 23(5): 647-654. 
16. Stubblefield M, et al. NCCN Task Force Report: Management of Neuropathy in 
Cancer. J of the National Comprehensive Cancer Network. 2009; 7: Suppl 5:S1-
S26. 
17. Armstrong T. Almadrones L. Gilbert MR: Chemotherapy-Induced Peripheral 
Neuropathy. Oncol Nurs Forum 32:305-311 2005. 
18. Woodgate R, Degner L F, Yanofsky R.  A different perspective to approaching 
cancer symptoms in children. J of Pain and Symptom Management. 2003;26 
(3):800-817. 
19. Montgomery M, Huang S, Cox CL, Leisenring W M, Et al. Physical therapy and 
chiropractic use among childhood cancer survivors with chronic disease: 
20. Gilchrist l, Tanner L. The pediatric-modified total neuropathy score: a reliable 
and valid measure of chemotherapy-induced peripheral neuropathy in children 
with non-cns cancers. Support Care Cancer. September 2012; 21:847-856. 
21. Gilchrist L, Marais L, Tanner, L. Comparison of two chemotherapy-induced 
peripheral neuropathy measurement approaches in children. Support Care 
Cancer. 2014;22(2):359-66. 
22. Wuang YP, Su CY. Reliability and responsiveness of the Bruininks-Oseretsky 
Test of Motor Proficiency-Second Edition in children with intellectual disability. 
Res Dev Disabil. 2009;30(5):847-55. 
 
 
37 
 
23. U.S. Food and Drug Administration. Data Standards Manual: Route of 
Administration. Available at: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequi
rements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071667.ht
m. Accessed April 30, 2014. 
24. Enskar K, von Essen L. Physical problems and psychosocial function in children 
with cancer. Paediatric Nursing. April 2008; 20(3):37-41.  
 
 
